Covidyte™ EN450 Substrate MAK373-100RXN

The coronavirus main protease, which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design. The inhibition of viral proteases necessary for proteolytic processing of polyproteins has been a successful strategy in the treatment of human immunodeficiency virus (HIV) and hepatitis C respectively, proving the potential of protease inhibitors for the treatment of viral infections. Similarly, the main protease of SARS-CoV-2 is thought to be essential for viral replication and is therefore regarded as a promising target for antiviral therapy of Covid-19.
Compatible with high-throughput handling systems.
Suitable for developing methods to screen potential inhibitors of coronavirus proteases
Covidyte EN450 is a peptide substrate containing a 14-amino acid sequence that can be cleaved by coronavirus proteases. The dark-FRET peptide contains Dabcyl (quencher) and Edans (donor) on the N-and C-terminals respectively where the fluorescence of Edans is effectively quenched by Dabcyl when the peptide is intact. When the peptide is hydrolyzed by coronavirus proteases, the Edans fragment generates significantly enhanced fluorescence since its fluorescence is no longer quenched by Dabcyl. The activity of coronavirus proteases can be effectively monitored by the fluorescence intensity of Edans.
Covidyte is a trademark of AAT Bioquest, Inc.

usage	sufficient for 100 fluorometric tests
Quality Level	100,
detection method	fluorometric
storage temp.	20°C

WGK Germany	WGK 1
Flash Point F	Not applicable
Flash Point C	Not applicable